AMD

More frequent dosing for refractory nAMD?

A closer look at biweekly anti-VEGF dosing for chronic disease that doesn’t respond completely to standard monthly dosing.

New revelations for nAMD, CSC treatments and ILM utility

Trial readouts on improving treatment durability, a potential new therapy for central serous chorioretinopathy and adding to the debate of RRD repair.

Gene therapy in AMD: Promises and challenges

Gene therapy could offer long-term stable control and prevent non-compliance, but the long-term effectiveness remains to be seen.

Gene therapy and editing for the retina: A primer

A look at advances in gene replacement therapy, gene delivery and CRISPR technology.

Is drier better in neovascular AMD?

It may depend on the location of the fluid. A quick look at HARBOR post-hoc results.

Pipeline Report: Despite major approvals, the queue gets longer

Treatments for exudative disease were notable for four significant exits from our listing and seven new entries this year.

Pipeline Report: The path to GA treatment: What’s hot, what’s not

A review of past trials that disappointed and current trials that are showing promise as potential treatments.

First results of gene and cell therapies for nAMD, RP, plus ...

Findings on predictors of endophthalmitis, widefield OCT-A vs. FA and microsecond pulsing laser make five worthy takeaways.

Downside of finger flicks, upside of abicipar changes

These findings and three other presentations on SRF/IRF, stable CST and oral therapy give new insights into nAMD.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.